Sort by
Items per page

Send to

Choose Destination

Best matches for Österborg A[au]:

Search results

Items: 1 to 50 of 218


Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A; Swedish CLL Group.

Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4. No abstract available.


First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L.

Haematologica. 2019 Apr;104(4):797-804. doi: 10.3324/haematol.2018.200204. Epub 2018 Nov 22.


Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv271. doi: 10.1093/annonc/mdy323. No abstract available.


Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Palma M, Krstic A, Peña Perez L, Berglöf A, Meinke S, Wang Q, Blomberg KEM, Kamali-Moghaddam M, Shen Q, Jaremko G, Lundin J, De Paepe A, Höglund P, Kimby E, Österborg A, Månsson R, Smith CIE.

Br J Haematol. 2018 Oct;183(2):212-224. doi: 10.1111/bjh.15516. Epub 2018 Aug 20.


HAX-1 overexpression in multiple myeloma is associated with poor survival.

Feng X, Kwiecinska A, Rossmann E, Bottai M, Ishikawa T, Patarroyo M, Österborg A, Porwit A, Zheng C, Fadeel B.

Br J Haematol. 2019 Apr;185(1):179-183. doi: 10.1111/bjh.15430. Epub 2018 Jun 19. No abstract available.


Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.

Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM.

Br J Haematol. 2018 Aug;182(4):504-512. doi: 10.1111/bjh.15421. Epub 2018 Jun 5.


A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.

Daneshmanesh AH, Hojjat-Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, Vågberg J, Byström S, Olsson E, Olin T, Österborg A, Mellstedt H.

PLoS One. 2018 Jun 1;13(6):e0198038. doi: 10.1371/journal.pone.0198038. eCollection 2018.


First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.

Hojjat-Farsangi M, Daneshmanesh AH, Khan AS, Shetye J, Mozaffari F, Kharaziha P, Rathje LS, Kokhaei P, Hansson L, Vågberg J, Byström S, Olsson E, Löfberg C, Norström C, Schultz J, Norin M, Olin T, Österborg A, Mellstedt H, Moshfegh A.

Leukemia. 2018 Oct;32(10):2291-2295. doi: 10.1038/s41375-018-0113-1. Epub 2018 Mar 27. No abstract available.


Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Palma M, Hansson L, Mulder TA, Adamson L, Näsman-Glaser B, Eriksson I, Heimersson K, Ryblom H, Mozaffari F, Svensson A, Gentilcore G, Österborg A, Mellstedt H.

Eur J Haematol. 2018 Jul;101(1):68-77. doi: 10.1111/ejh.13065. Epub 2018 May 22.


Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv96-iv110. doi: 10.1093/annonc/mdx758. No abstract available.


Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells.

Kokhaei P, Hojjat-Farsangi M, Mozaffari F, Moshfegh A, Pak F, Rashidy-Pour A, Palma M, Hansson L, Österborg A, Mellstedt H.

PLoS One. 2018 Feb 12;13(2):e0192839. doi: 10.1371/journal.pone.0192839. eCollection 2018.


CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Magalhaes I, Kalland I, Kochenderfer JN, Österborg A, Uhlin M, Mattsson J.

J Immunother. 2018 Feb/Mar;41(2):73-83. doi: 10.1097/CJI.0000000000000193.


The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

Alzrigat M, Párraga AA, Majumder MM, Ma A, Jin J, Österborg A, Nahi H, Nilsson K, Heckman CA, Öberg F, Kalushkova A, Jernberg-Wiklund H.

Oncotarget. 2017 Oct 20;8(61):103731-103743. doi: 10.18632/oncotarget.21909. eCollection 2017 Nov 28.


Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.

Hansson L, Asklid A, Diels J, Eketorp-Sylvan S, Repits J, Søltoft F, Jäger U, Österborg A.

Ann Hematol. 2017 Oct;96(10):1681-1691. doi: 10.1007/s00277-017-3061-3. Epub 2017 Jul 31.


Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Winqvist M, Palma M, Heimersson K, Mellstedt H, Österborg A, Lundin J.

Br J Haematol. 2018 Aug;182(4):590-594. doi: 10.1111/bjh.14836. Epub 2017 Jul 5. No abstract available.


EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.

Alzrigat M, Párraga AA, Agarwal P, Zureigat H, Österborg A, Nahi H, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H.

Oncotarget. 2017 Feb 7;8(6):10213-10224. doi: 10.18632/oncotarget.14378.


T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.

Palma M, Gentilcore G, Heimersson K, Mozaffari F, Näsman-Glaser B, Young E, Rosenquist R, Hansson L, Österborg A, Mellstedt H.

Haematologica. 2017 Mar;102(3):562-572. doi: 10.3324/haematol.2016.151100. Epub 2016 Dec 7.


Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.

Asklid A, Winqvist M, Eketorp Sylvan S, Mattsson A, Björgvinsson E, Søltoft F, Repits J, Diels J, Österborg A, Hansson L.

Leuk Lymphoma. 2017 May;58(5):1219-1223. doi: 10.1080/10428194.2016.1246727. Epub 2016 Nov 28. No abstract available.


Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J.

Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4.


Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.

Stauder R, Eichhorst B, Hamaker ME, Kaplanov K, Morrison VA, Österborg A, Poddubnaya I, Woyach JA, Shanafelt T, Smolej L, Ysebaert L, Goede V.

Ann Oncol. 2017 Feb 1;28(2):218-227. doi: 10.1093/annonc/mdw547.


Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia.

Khan AS, Hojjat-Farsangi M, Daneshmanesh AH, Hansson L, Kokhaei P, Österborg A, Mellstedt H, Moshfegh A.

Tumour Biol. 2016 Sep;37(9):11947-11957. Epub 2016 Apr 16.


Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Högfeldt T, Jaing C, Loughlin KM, Thissen J, Gardner S, Bahnassy AA, Gharizadeh B, Lundahl J, Österborg A, Porwit A, Zekri AN, Khaled HM, Mellstedt H, Moshfegh A.

Oncol Lett. 2016 Oct;12(4):2782-2788. Epub 2016 Aug 16.


Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S.

Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13.


Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A.

Haematologica. 2016 Dec;101(12):1573-1580. Epub 2016 May 19.


New perspectives on complement mediated immunotherapy.

Stasiłojć G, Österborg A, Blom AM, Okrój M.

Cancer Treat Rev. 2016 Apr;45:68-75. doi: 10.1016/j.ctrv.2016.02.009. Epub 2016 Mar 8. Review.


Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.

Österborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G, Kaplan P, Steurer M, Schuh A, Montillo M, Kryachok I, Middeke JM, Kulyaba Y, Rekhtman G, Gorczyca M, Daly S, Chang CN, Lisby S, Gupta I.

Leuk Lymphoma. 2016 Sep;57(9):2037-46. doi: 10.3109/10428194.2015.1122783. Epub 2016 Jan 19.


Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Agarwal P, Alzrigat M, Párraga AA, Enroth S, Singh U, Ungerstedt J, Österborg A, Brown PJ, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H.

Oncotarget. 2016 Feb 9;7(6):6809-23. doi: 10.18632/oncotarget.6843.


Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.

Hojjat-Farsangi M, Jeddi-Tehrani M, Daneshmanesh AH, Mozaffari F, Moshfegh A, Hansson L, Razavi SM, Sharifian RA, Rabbani H, Österborg A, Mellstedt H, Shokri F.

PLoS One. 2015 Nov 12;10(11):e0142310. doi: 10.1371/journal.pone.0142310. eCollection 2015.


Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

Kokhaei P, Jadidi-Niaragh F, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M.

J Drug Target. 2016;24(5):373-85. doi: 10.3109/1061186X.2015.1086357. Epub 2015 Sep 11. Review.


Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study.

Sylvan SE, Skribek H, Norin S, Muhari O, Österborg A, Szekely L.

Exp Hematol. 2016 Jan;44(1):38-49.e1. doi: 10.1016/j.exphem.2015.08.009. Epub 2015 Aug 29.


Targets for Ibrutinib Beyond B Cell Malignancies.

Berglöf A, Hamasy A, Meinke S, Palma M, Krstic A, Månsson R, Kimby E, Österborg A, Smith CI.

Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. Review.


Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.

Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ.

Br J Haematol. 2015 Jul;170(1):40-9. doi: 10.1111/bjh.13380. Epub 2015 Mar 30.


Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation.

Blom AM, Österborg A, Mollnes TE, Okroj M.

Mol Immunol. 2015 Aug;66(2):164-70. doi: 10.1016/j.molimm.2015.02.029. Epub 2015 Mar 18.


Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.

Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Österborg A, Lundqvist A.

Eur J Immunol. 2015 Jun;45(6):1783-93. doi: 10.1002/eji.201444885. Epub 2015 Apr 17.


Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.

Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG; Hx-CD20-406 Study Investigators.

Haematologica. 2015 Aug;100(8):e311-4. doi: 10.3324/haematol.2014.121459. Epub 2015 Mar 13. No abstract available.


Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Rossmann E, Österborg A, Löfvenberg E, Choudhury A, Forssmann U, von Heydebreck A, Schröder A, Mellstedt H.

Hum Vaccin Immunother. 2014;10(11):3394-408. doi: 10.4161/hv.29918.


The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.

Daneshmanesh AH, Hojjat-Farsangi M, Moshfegh A, Khan AS, Mikaelsson E, Österborg A, Mellstedt H.

Br J Haematol. 2015 May;169(3):455-8. doi: 10.1111/bjh.13228. Epub 2014 Nov 19. No abstract available.


The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.

Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H.

Semin Cancer Biol. 2014 Dec;29:21-31. doi: 10.1016/j.semcancer.2014.07.005. Epub 2014 Jul 25. Review.


The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.

Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH, Howes A.

Future Oncol. 2015;11(1):51-9. doi: 10.2217/fon.14.119.


A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.

Ludwig H, Aapro M, Bokemeyer C, Glaspy J, Hedenus M, Littlewood TJ, Österborg A, Rzychon B, Mitchell D, Beguin Y.

Support Care Cancer. 2014 Aug;22(8):2197-206.


Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.

Mikaelsson E, Osterborg A, Tahmasebi Fard Z, Mahmoudi A, Mahmoudian J, Jeddi-Tehrani M, Akhondi M, Shokri F, Bishop PN, Rabbani H, Mellstedt H.

Exp Hematol Oncol. 2013 Aug 28;2(1):23. doi: 10.1186/2162-3619-2-23.


Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.

Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC.

J Clin Pharmacol. 2014 Jul;54(7):818-27. doi: 10.1002/jcph.268. Epub 2014 Jan 28.


Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review.

Beguin Y, Aapro M, Ludwig H, Mizzen L, Osterborg A.

Crit Rev Oncol Hematol. 2014 Jan;89(1):1-15. doi: 10.1016/j.critrevonc.2013.10.008. Epub 2013 Nov 8. Review.


Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.

Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, Osterborg A.

Leuk Lymphoma. 2014 Aug;55(8):1774-80. doi: 10.3109/10428194.2013.827786. Epub 2014 Feb 4.


The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.

Hojjat-Farsangi M, Khan AS, Daneshmanesh AH, Moshfegh A, Sandin A, Mansouri L, Palma M, Lundin J, Österborg A, Mellstedt H.

PLoS One. 2013 Oct 24;8(10):e78339. doi: 10.1371/journal.pone.0078339. eCollection 2013.


Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.

Okroj M, Eriksson I, Österborg A, Blom AM.

Med Oncol. 2013 Dec;30(4):759. doi: 10.1007/s12032-013-0759-5. Epub 2013 Nov 7.


Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.

Högfeldt T, Johnsson P, Grandér D, Bahnassy AA, Porwit A, Eid S, Österborg A, Zekri AR, Lundahl J, Khaled MH, Mellstedt H, Moshfegh A.

Leuk Lymphoma. 2014 May;55(5):1158-65. doi: 10.3109/10428194.2013.824077. Epub 2013 Aug 31.


A proline/arginine-rich end leucine-rich repeat protein (PRELP) variant is uniquely expressed in chronic lymphocytic leukemia cells.

Mikaelsson E, Österborg A, Jeddi-Tehrani M, Kokhaei P, Ostadkarampour M, Hadavi R, Gholamin M, Akhondi M, Shokri F, Rabbani H, Mellstedt H.

PLoS One. 2013 Jun 24;8(6):e67601. doi: 10.1371/journal.pone.0067601. Print 2013.


Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia.

Palma M, Parker A, Hojjat-Farsangi M, Forster J, Kokhaei P, Hansson L, Osterborg A, Mellstedt H.

Exp Hematol. 2013 Jul;41(7):615-26. doi: 10.1016/j.exphem.2013.03.008. Epub 2013 Mar 30.


An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.

Lin H, Kolosenko I, Björklund AC, Protsyuk D, Österborg A, Grandér D, Tamm KP.

Exp Cell Res. 2013 Mar 10;319(5):600-11. doi: 10.1016/j.yexcr.2012.12.006. Epub 2012 Dec 13.


Supplemental Content

Loading ...
Support Center